More Trouble Looming for Amarin Corporation?

Teva announced yesterday that it's launching a generic version of GlaxoSmithKline's Lovaza. Will this launch hurt Amarin's competing product?

Apr 9, 2014 at 2:30PM

Amarin Corp. (NASDAQ:AMRN) can't seem to catch a break these days. Almost immediately after inking a co-promotional deal for the company's lone commercial product, Vascepa, with Kowa Pharmaceuticals America, Teva Pharmaceuticals (NYSE:TEVA) announced yesterday they are launching a generic version of Lovaza. Lovaza is Vascepa's chief rival in the severe triglyceride market, and is manufactured by GlaxoSmithKline (NYSE:GSK). This generic launch is presumably bad news for Amarin because it could hurt Vascepa's sales as well.


Source: Wikipedia.

Amarin's recent 10-K reported that Lovaza saw sales of $1.4 billion in 2013, whereas Vascepa generated $26.4 million in revenue for the year, most of which came in the fourth quarter, suggesting the drug was beginning to gain traction. Amarin bulls have long pointed to Lovaza's blockbuster status as evidence that Vascepa could be a commercial success as well, even after the drug failed to gain approval from the Food and Drug Administration for a label expansion as a treatment for moderately high triglycerides last year through the ANCHOR indication . As Amarin shares moved lower on the back of this news yesterday, I think it's important to consider how generic Lovaza could impact Vascepa going forward. 

Will generic Lovaza halt Vascepa's recent sales momentum?
To be up front, I don't think this question can be answered definitively right now. How generic Lovaza will impact this market is clouded, in my opinion, by two overhanging issues that are worth exploring in their own right. 

First off, although it seems straightforward that another player in the market with a cheaper price should translate into lower sales for higher-priced brand names, this is not always the case. For instance, Abbot Laboratories successfully fended off generic rivals to its cholesterol-lowering drug, Tricor, in patients at risk of cardiovascular disease for over a decade using a complex reformulation strategy. And Mylan has only recently started to cut into Tricor's sales with its generic version of the drug, showing the effectiveness of Abbot's strategy in warding off generic competitors. GlaxoSmithKline and/or Amarin could thus choose to follow in Abbot's footsteps in the wake of Teva's planned entry into the market with its generic. While I don't know what exactly they will do -- this is just one possible route -- I don't expect either company to remain complacent while Teva gobbles up market share. 

Secondly, we don't know how Kowa plans to market Vascepa. As Vascepa reportedly has a better efficacy profile in terms of lowering triglycerides than Lovaza, Kowa will probably use this information to its advantage. The goal will obviously be to differentiate Lovaza and Vascepa in the eyes of doctors, thus increasing the barrier for generic competition. Overall, there will probably be some impact from generic Lovaza on Vascepa, but there are too many moving parts to this story to panic just yet.  

Foolish takeaways
Amarin's management has been open about the potential impact of a generic launch of Lovaza for some time, and that day has finally arrived. Even so, I would caution investors from overreacting to this development. Kowa is a highly experienced marketing partner in the cholesterol drug market and there are potential avenues worth exploring that could create a lucrative niche for Vascepa even now. While I am not exactly bullish on Amarin shares, I don't see generic Lovaza as a "straw that broke the camel's back" type event, either. In short, we need data on sales going forward to truly assess the impact of generic Lovaza, which won't come for a few months.

Looking ahead, the more pressing issue is Amarin's ability to fund its pivotal REDUCE-IT study. Unless sales of Vascepa improve markedly over the next few quarters, the company will be forced to either raise funds or discontinue the study altogether. In short, Amarin does have bigger problems to worry about than generic Lovaza, some of which, like the financing of REDUCE-IT, are critical to the company's future prospects.

3 stocks poised to be multi-baggers
Amarin has a lot of question marks, and it's in a highly competitive industry -- but investors know that the one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information